Hostname: page-component-848d4c4894-pjpqr Total loading time: 0 Render date: 2024-06-20T14:35:12.921Z Has data issue: false hasContentIssue false

Metabolic abnormality in the right dorsolateral prefrontal cortex in patients with obsessive–compulsive disorder: proton magnetic resonance spectroscopy

Published online by Cambridge University Press:  17 October 2016

Shin-Eui Park
Interdisciplinary Program of Biomedical Engineering, Chonnam National University, Gwangju, Republic of Korea
Nam-Gil Choi
Department of Radiology, DongShin University, Naju, Republic of Korea
Gwang-Woo Jeong*
Interdisciplinary Program of Biomedical Engineering, Chonnam National University, Gwangju, Republic of Korea Department of Radiology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea
Professor Gwang-Woo Jeong, Department of Radiology, Chonnam National University Hospital, Chonnam National University Medical School, # 42 Jebongro, Dong-gu, Gwangju 501-757, Republic of Korea. Tel: +82 62 220 5881; Fax: +82 62 226 4380; E-mail:



Proton magnetic resonance spectroscopy (1H-MRS) was used to evaluate metabolic changes in the dorsolateral prefrontal cortex (DLPFC) in patients with obsessive–compulsive disorder (OCD).


In total, 14 OCD patients (mean age 28.9±7.2 years) and 14 healthy controls (mean age 32.6±7.1 years) with no history of neurological and psychiatric illness participated in this study. Brain metabolite concentrations were measured from a localised voxel on the right DLPFC using a 3-Tesla 1H-MRS.


The metabolic concentration of myo-inositol in patients with OCD increased significantly by 52% compared with the healthy controls, whereas glutamine/glutamate was decreased by 11%. However, there were no significant differences in N-acetylaspartate, choline, lactate and lipid between the two groups.


These findings would be helpful to understand the pathophysiology of OCD associated with the brain metabolic abnormalities in the right DLPFC.

Original Articles
© Scandinavian College of Neuropsychopharmacology 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (text revision), 5th edn. Washington, DC: American Psychiatric Association, 2013.Google Scholar
2. Karno, M, Golding, JM, Sorenson, SB et al. The epidemiology of obsessive compulsive disorder in five US communities. Arch Gen Psychiatry 1988;45:10941099.Google Scholar
3. Zohar, J, Chopra, M, Sasson, Y et al. Obsessive compulsive disorder: serotonin and beyond. World J Biol Psychiatry 2000;1:92100.Google Scholar
4. Greist, JH, Jefferson, JW, Kobak, KA et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry 1995;52:5360.CrossRefGoogle ScholarPubMed
5. Russell, A, Cortese, B, Lorch, E et al. Localized functional neurochemical marker abnormalities in dorsolateral prefrontal cortex in pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2003;13(Suppl. 1):s31s38.Google Scholar
6. Ebert, D, Speck, O, König, A et al. 1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: evidence for neuronal loss in the cingulate gyrus and the right striatum. Psychiatry Res 1997;74:173176.Google Scholar
7. Bartha, R, Stein, MB, Williamson, PC et al. A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects. Am J Psychiatry 1998;155:15841591.Google Scholar
8. Simpson, HB, Shungu, DC, Bender, J Jr. et al. Investigation of cortical glutamate-glutamine and γ-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy. Neuropsychopharmacology 2012;37:26842692.Google Scholar
9. Simpson, HB, Kegeles, LS, Hunter, L et al. Assessment of glutamate in striatal subregions in obsessive-compulsive disorder with proton magnetic resonance spectroscopy. Psychiatry Res 2015;232:6570.Google Scholar
10. Rosenberg, DR, MacMaster, FP, Keshavan, MS et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000;39:10961103.Google Scholar
11. Ohara, K, Isoda, H, Suzuki, Y et al. Proton magnetic resonance spectroscopy of lenticular nuclei in obsessive-compulsive disorder. Psychiatry Res 1999;92:8391.Google Scholar
12. den Braber, A, van ‘t Ent, D, Cath, DC et al. Brain activation during cognitive planning in twins discordant or concordant for obsessive-compulsive symptoms. Brain 2010;133:31233140.Google Scholar
13. Togao, O, Yoshiura, T, Nakao, T et al. Regional gray and white matter volume abnormalities in obsessive-compulsive disorder: a voxel-based morphometry study. Psychiatry Res 2010;184:2937.Google Scholar
14. Sachdev, PS, McBride, R, Loo, CK et al. Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: a preliminary investigation. J Clin Psychiatry 2001;62:981984.Google Scholar
15. Alvarenga, PG, do Rosário, MC, Batistuzzo, MC et al. Obsessive-compulsive symptom dimensions correlate to specific gray matter volumes in treatment-naïve patients. J Psychiatr Res 2012;46:16351642.Google Scholar
16. Goodman, WK, Price, LH, Rasmussen, SA et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989;46:10121016.CrossRefGoogle ScholarPubMed
17. Reyngoudt, H, Claeys, T, Vlerick, L et al. Age-related differences in metabolites in the posterior cingulate cortex and hippocampus of normal ageing brain: a 1H-MRS study. Eur J Radiol 2012;81:e223e231.CrossRefGoogle Scholar
18. Milad, MR, Rauch, SL. Obsessive compulsive disorder: beyond segregated cortico striatal pathway. Trends Cogn Sci 2012;16:4351.CrossRefGoogle Scholar
19. Ting, JT, Feng, G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics 2008;2:6275.Google Scholar
20. Whiteside, SP, Port, JD, Deacon, BJ et al. A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety. Psychiatry Res 2006;146:137147.CrossRefGoogle ScholarPubMed
21. Rosenberg, DR, Mirza, Y, Russell, A et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 2004;43:11461153.CrossRefGoogle ScholarPubMed
22. Rosenberg, DR, Keshavan, MS. A.E. Bennett Research Award. Toward a neurodevelopmental model of obsessive-compulsive disorder. Biol Psychiatry 1998;43:623640.Google Scholar
23. Szeszko, PR, MacMillan, S, McMeniman, M et al. Brain structural abnormalities in psychotropic drug-naive pediatric patients with obsessive-compulsive disorder. Am J Psychiatry 2004;161:10491056.CrossRefGoogle ScholarPubMed
24. Keshavan, MS. Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J Psychiatr Res 1999;33:513521.Google Scholar
25. Kim, H, McGrath, BM, Silverstone, PH. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders-focus on magnetic resonance spectroscopy (MRS) studies. Hum Psychopharmacol 2005;20:309326.Google Scholar
26. Vaden, DL, Ding, D, Peterson, B et al. Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J Biol Chem 2001;27:1546615471.Google Scholar
27. Chang, L, Ernst, T, Grob, CS et al. Cerebral (1)H MRS alterations in recreational 3, 4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) users. J Magn Reson Imaging 1999;10:521526.Google Scholar